The Role of Gut Microflora and the Cholinergic Anti-inflammatory Neuroendocrine System in Diabetes Mellitus

Frontiers in Endocrinology

Volumn 7, Issue , 2016, Pages

  Parekh, Parth J ^a   Nayi, Vipul R ^b   Johnson, David A ^c   Vinik, Aaron I ^c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

autonomic nervous system; diabetes; intestinal dysbiosis; intestinal microbiome; metabolic syndrome; obesity

Indexed keywords

EID: 84995584992     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2016.00055     Document Type: Review

References (89)

1. Amed S Dean HJ Panagiotopoulos C Sellers EA Hadjiyannakis S Laubscher TA et al. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care (2010) 33:786–91.10.2337/dc09-101320067956
2. Pinhas-Hamiel O Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr (2005) 146:693–700.10.1016/j.jpeds.2004.12.042
3. Pittenger GL Taylor-Fishwick D Vinik AI. A role for islet neogenesis in curing diabetes. Diabetologia (2009) 52:735–8.10.1007/s00125-009-1322-y
4. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 58:773–95.10.2337/db09-9028
5. Vinik AI. The conductor of the autonomic orchestra. Front Endocrinol (2012) 3:71.10.3389/fendo.2012.0007122737143
6. Vinik A Maser R Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabet Med (2011) 28:643–51.10.1111/j.1464-5491.2010.03184.x21569084
7. Parekh PJ Arusi E Vinik AI Johnson DA. The role and influence of gut microbiota in pathogenesis and management of obesity and metabolic syndrome. Front Endocrinol (2014) 5:47.10.3389/fendo.2014.00047
8. Calle MC Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab (2012) 38:183–91.10.1016/j.diabet.2011.11.00622252015
9. Moschen AR Molnar C Enrich B Geiger S Ebenbichler CF Tilg H. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med (2011) 17:840–5.10.2119/molmed.2010.0010821394384
10. van Greevenbroek MM Schalkwijk CG Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med (2013) 71:174–87.23723111
11. Cani PD Amar J Iglesias MA Poggi M Knauf C Bastelica D et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 56:1761–72.10.2337/db06-1491
12. Remely M Aumueller E Jahn D Hippe B Brath H Haslberger AG. Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity. Benef Microbes (2014) 5:33–43.10.3920/BM2013.00624533976
13. Hooper LV Stappenbeck TS Hong CV Gordon JI. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol (2003) 4(3):269–73.10.1038/ni88812548285
14. Geurts L Lazarevic V Derrien M Everard A Van RM Knauf C et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol (2011) 2:149.10.3389/fmicb.2011.0014921808634
15. Geurts L Neyrinck AM Delzenne NM Knauf C Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes (2014) 5:3–17.10.3920/BM2012.006523886976
16. Cani PD Osto M Geurts L Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes (2012) 3:279–88.10.4161/gmic.1962522572877
17. Qin J Li Y Cai Z Li S Zhu J Zhang F et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 490:55–60.10.1038/nature1145023023125
18. Karlsson FH Tremaroli V Nookaew I Bergstrom G Behre CJ Fagerberg B et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature (2013) 498:99–103.10.1038/nature1219823719380
19. Fallucca F Porrata C Fallucca S Pianesi M. Influence of diet on gut microbiota, inflammation and type 2 diabetes mellitus. First experience with macrobiotic Ma-Pi 2 diet. Diabetes Metab Res Rev (2014) 30(Suppl 1):48–54.10.1002/dmrr.251824532292
20. Fallucca F Fontana L Fallucca S Pianesi M. Gut microbiota and Ma-Pi 2 macrobiotic diet in the treatment of type 2 diabetes. World J Diabetes (2015) 6:403–11.10.4239/wjd.v6.i3.40325897351
21. Soare A Del TR Roncella E Khazrai YM Angeletti S Dugo L et al. The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial. BMJ Open Diabetes Res Care (2015) 3:e000079.10.1136/bmjdrc-2014-00007925852946
22. Soare A Khazrai YM Del TR Roncella E Fontana L Fallucca S et al. The effect of the macrobiotic Ma-Pi 2 diet vs. the recommended diet in the management of type 2 diabetes: the randomized controlled MADIAB trial. Nutr Metab (Lond) (2014) 11:39.10.1186/1743-7075-11-3925302069
23. Porrata C Sanchez J Correa V Abuin A Hernandez-Triana M Dacosta-Calheiros RV et al. Ma-pi 2 macrobiotic diet intervention in adults with type 2 diabetes mellitus. MEDICC Rev (2009) 11:29–35.21483296
24. Chen P Zhang Q Dang H Liu X Tian F Zhao J et al. Antidiabetic effect of Lactobacillus casei CCFM0412 on mice with type 2 diabetes induced by a high-fat diet and streptozotocin. Nutrition (2014) 30:1061–8.10.1016/j.nut.2014.03.02225102821
25. Zhang Y Guo X Guo J He Q Li H Song Y et al. Lactobacillus casei reduces susceptibility to type 2 diabetes via microbiota-mediated body chloride ion influx. Sci Rep (2014) 4:5654.10.1038/srep0565425133590
26. Matsuzaki T Yamazaki R Hashimoto S Yokokura T. Antidiabetic effects of an oral administration of Lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-Ay mice. Endocr J (1997) 44:357–65.10.1507/endocrj.44.3579279510
27. Yadav H Jain S Sinha PR. Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J Dairy Res (2008) 75:189–95.10.1017/S002202990800312918474136
28. Matsuzaki T Nagata Y Kado S Uchida K Kato I Hashimoto S et al. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS (1997) 105:643–9.10.1111/j.1699-0463.1997.tb05066.x9298104
29. Naito E Yoshida Y Makino K Kounoshi Y Kunihiro S Takahashi R et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol (2011) 110:650–7.10.1111/j.1365-2672.2010.04922.x21281408
30. Everard A Belzer C Geurts L Ouwerkerk JP Druart C Bindels LB et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A (2013) 110:9066–71.10.1073/pnas.121945111023671105
31. Santacruz A Collado MC Garcia-Valdes L Segura MT Martin-Lagos JA Anjos T et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr (2010) 104:83–92.10.1017/S000711451000017620205964
32. Karlsson CL Onnerfalt J Xu J Molin G Ahrne S Thorngren-Jerneck K. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring) (2012) 20:2257–61.10.1038/oby.2012.11022546742
33. Derrien M Vaughan EE Plugge CM de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol (2004) 54:1469–76.10.1099/ijs.0.02873-015388697
34. Cani PD Everard A. [Akkermansia muciniphila: a novel target controlling obesity, type 2 diabetes and inflammation?]. Med Sci (Paris) (2014) 30:125–7.10.1051/medsci/20143002003
35. Graessler J Qin Y Zhong H Zhang J Licinio J Wong ML et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J (2013) 13:514–22.10.1038/tpj.2012.4323032991
36. de Vos WM de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev (2012) 70(Suppl 1):S45–56.10.1111/j.1753-4887.2012.00505.x22861807
37. Suez J Korem T Zeevi D Zilberman-Schapira G Thaiss CA Maza O et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature (2014) 514:181–6.10.1038/nature1379325231862
38. Remely M Aumueller E Merold C Dworzak S Hippe B Zanner J et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene (2014) 537:85–92.10.1016/j.gene.2013.11.08124325907
39. Li M Wang B Zhang M Rantalainen M Wang S Zhou H et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A (2008) 105:2117–22.10.1073/pnas.071203810518252821
40. Miquel S Martin R Rossi O Bermudez-Humaran LG Chatel JM Sokol H et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol (2013) 16:255–61.10.1016/j.mib.2013.06.00323831042
41. Greiner T Backhed F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab (2011) 22:117–23.10.1016/j.tem.2011.01.00221353592
42. Furet JP Kong LC Tap J Poitou C Basdevant A Bouillot JL et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes (2010) 59:3049–57.10.2337/db10-025320876719
43. Parekh PJ Balart LA Johnson DA. The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease. Clin Transl Gastroenterol (2015) 6:e91.10.1038/ctg.2015.1626087059
44. Quevrain E Maubert MA Michon C Chain F Marquant R Tailhades J et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut (2016) 65(3):415–25.10.1136/gutjnl-2014-30764926045134
45. Barengolts E. Vitamin D and prebiotics may benefit the intestinal microbacteria and improve glucose homeostasis in prediabetes and type 2 diabetes. Endocr Pract (2013) 19:497–510.10.4158/EP12263.RA23823585
46. Panwar H Rashmi HM Batish VK Grover S. Probiotics as potential biotherapeutics in the management of type 2 diabetes – prospects and perspectives. Diabetes Metab Res Rev (2013) 29:103–12.10.1002/dmrr.237623225499
47. Delzenne NM Kok N. Effects of fructans-type prebiotics on lipid metabolism. Am J Clin Nutr (2001) 73:456S–8S.11157357
48. Delzenne NM Neyrinck AM Backhed F Cani PD. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol (2011) 7:639–46.10.1038/nrendo.2011.12621826100
49. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature (2012) 486:207–14.10.1038/nature11234
50. Ley RE Turnbaugh PJ Klein S Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature (2006) 444:1022–3.10.1038/4441022a17183309
51. Everard A Lazarevic V Derrien M Girard M Muccioli GG Neyrinck AM et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes (2011) 60:2775–86.10.2337/db11-022721933985
52. Cani PD Knauf C Iglesias MA Drucker DJ Delzenne NM Burcelin R. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes (2006) 55:1484–90.10.2337/db05-136016644709
53. Wu X Ma C Han L Nawaz M Gao F Zhang X et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol (2010) 61:69–78.10.1007/s00284-010-9582-920087741
54. Cani PD Lecourt E Dewulf EM Sohet FM Pachikian BD Naslain D et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr (2009) 90:1236–43.10.3945/ajcn.2009.2809519776140
55. Cani PD Dewever C Delzenne NM. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br J Nutr (2004) 92:521–6.10.1079/BJN2004122515469657
56. Cani PD Neyrinck AM Maton N Delzenne NM. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1. Obes Res (2005) 13:1000–7.10.1038/oby.2005.11715976142
57. Cani PD Possemiers S Van de Wiele T Guiot Y Everard A Rottier O et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut (2009) 58:1091–103.10.1136/gut.2008.16588619240062
58. Ejtahed HS Mohtadi-Nia J Homayouni-Rad A Niafar M Asghari-Jafarabadi M Mofid V et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci (2011) 94:3288–94.10.3168/jds.2010-412821700013
59. Tabuchi M Ozaki M Tamura A Yamada N Ishida T Hosoda M et al. Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem (2003) 67:1421–4.10.1271/bbb.67.142112843677
60. Calcinaro F Dionisi S Marinaro M Candeloro P Bonato V Marzotti S et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia (2005) 48:1565–75.10.1007/s00125-005-1831-215986236
61. Ma X Hua J Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol (2008) 49:821–30.10.1016/j.jhep.2008.05.02518674841
62. Amar J Chabo C Waget A Klopp P Vachoux C Bermudez-Humaran LG et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med (2011) 3:559–72.10.1002/emmm.20110015921735552
63. Gomes AC Bueno AA de Souza RG Mota JF. Gut microbiota, probiotics and diabetes. Nutr J (2014) 13:60.10.1186/1475-2891-13-6024939063
64. Maritim AC Sanders RA Watkins JB III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol (2003) 17:24–38.10.1002/jbt.1005812616644
65. Edwards JF Casellini CM Parson HK Obrosova IG Yorek M Vinik AI. Role of peroxynitrite in the development of diabetic peripheral neuropathy. Diabetes Care (2015) 38:e100–1.10.2337/dc14-2918
66. Lieb DC Parson HK Mamikunian G Vinik AI. Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp Diabetes Res (2012) 2012:878760.10.1155/2012/87876022110481
67. Harris M Cowie C Stern M Boyko E Reiber G Bennett P. Diabetes in America. Bethesda, MD: National Institutes of Health (1995). p. 233–57.
68. Mohamadshahi M Veissi M Haidari F Javid AZ Mohammadi F Shirbeigi E. Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: a randomized controlled clinical trial. J Res Med Sci (2014) 19:531–6.25197295
69. Vinik AI Maser RE Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care (2010) 33:1688–90.10.2337/dc10-0745
70. Kootte RS Vrieze A Holleman F Dallinga-Thie GM Zoetendal EG de Vos WM et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab (2012) 14:112–20.10.1111/j.1463-1326.2011.01483.x21812894
71. Ridaura VK Faith JJ Rey FE Cheng J Duncan AE Kau AL et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science (2013) 341:1241214.10.1126/science.124121424009397
72. Vrieze A Van NE Holleman F Salojarvi J Kootte RS Bartelsman JF et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology (2012) 143:913–6.10.1053/j.gastro.2012.06.03122728514
73. Borovikova LV Ivanova S Zhang M Yang H Botchkina GI Watkins LR et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 405:458–62.10.1038/3501307010839541
74. Tracey KJ. Reflex control of immunity. Nat Rev Immunol (2009) 9:418–28.10.1038/nri2566
75. Saravia F Homo-Delarche F. Is innervation an early target in autoimmune diabetes? Trends Immunol (2003) 24:574–9.10.1016/j.it.2003.09.01014596878
76. Razavi R Chan Y Afifiyan FN Liu XJ Wan X Yantha J et al. TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell (2006) 127:1123–35.10.1016/j.cell.2006.10.03817174891
77. Watkins LR Goehler LE Relton JK Tartaglia N Silbert L Martin D et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett (1995) 183:27–31.10.1016/0304-3940(94)11105-R7746479
78. Hansen MK O’Connor KA Goehler LE Watkins LR Maier SF. The contribution of the vagus nerve in interleukin-1beta-induced fever is dependent on dose. Am J Physiol Regul Integr Comp Physiol (2001) 280:R929–34.11247812
79. Goehler LE Relton JK Dripps D Kiechle R Tartaglia N Maier SF et al. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: a possible mechanism for immune-to-brain communication. Brain Res Bull (1997) 43:357–64.10.1016/S0361-9230(97)00020-89227848
80. Paolisso G Manzella D Montano N Gambardella A Varricchio M. Plasma leptin concentrations and cardiac autonomic nervous system in healthy subjects with different body weights. J Clin Endocrinol Metab (2000) 85:1810–4.10.1210/jcem.85.5.651110843157
81. Wakabayashi S Aso Y. Adiponectin concentrations in sera from patients with type 2 diabetes are negatively associated with sympathovagal balance as evaluated by power spectral analysis of heart rate variation. Diabetes Care (2004) 27:2392–7.10.2337/diacare.27.10.239215451906
82. Bernik TR Friedman SG Ochani M DiRaimo R Ulloa L Yang H et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med (2002) 195:781–8.10.1084/jem.2001171411901203
83. Van Maanen MA Vervoordeldonk MJ Tak PP. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis. Nat Rev Rheumatol (2009) 5:229–32.10.1038/nrrheum.2009.3119337288
84. Hara H Haga S Aoyama Y Kiriyama S. Short-chain fatty acids suppress cholesterol synthesis in rat liver and intestine. J Nutr (1999) 129:942–8.10222383
85. Raybould HE. Gut chemosensing: interactions between gut endocrine cells and visceral afferents. Auton Neurosci (2010) 153:41–6.10.1016/j.autneu.2009.07.00719674941
86. Bertrand PP. The cornucopia of intestinal chemosensory transduction. Front Neurosci (2009) 3:48.10.3389/neuro.21.003.200920582275
87. Goehler LE Gaykema RP Opitz N Reddaway R Badr N Lyte M. Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with Campylobacter jejuni. Brain Behav Immun (2005) 19:334–44.10.1016/j.bbi.2004.09.00215944073
88. Tanida M Yamano T Maeda K Okumura N Fukushima Y Nagai K. Effects of intraduodenal injection of Lactobacillus johnsonii La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats. Neurosci Lett (2005) 389:109–14.10.1016/j.neulet.2005.07.03616118039
89. Forsythe P Bienenstock J Kunze W. Vagal pathways for microbiome-brain-gut axis communication. In: Lyte M Cryan J, editors. Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease. New York: Springer (2014). p. 115–33.